Letters sent to healthcare professionals in June 2017

Letters were sent about Arsenic Trioxide (Trisenox), Uptravi▼ (selexipag), DepoCyte (cytarabine), Cinryze▼ (C1 esterase inhibitor [human]), and Clexane (enoxaparin sodium).

• From: Medicines and Healthcare products Regulatory Agency
• Published: 20 July 2017

• Therapeutic area: Cancer, Cardiovascular disease and lipidology, Haematology, Immunology and vaccination, Infectious disease, Paediatrics and neonatology, Respiratory disease and allergy, Urology and nephrology

In June 2017, the following letters were sent to relevant healthcare professionals:

• Arsenic Trioxide (Trisenox) 1 mg/mL concentrate for solution for infusion: importation and over-labelling of United States (US) Trisenox stock as Teva UK interim supply

• Uptravi▼ (selexipag): concomitant use with strong CYP2C8 inhibitors (eg, gemfibrozil) now contraindicated

• Cinryze▼ (C1 esterase inhibitor [human]): recommendations to prescribers in view of a potential supply shortage

• DepoCyte (cytarabine): follow-up on EU supply issue

• Clexane (enoxaparin sodium): updates to strength expression, dose regimens in DVT/PE, use in patients with severe renal impairment

Article citation: Drug Safety Update volume 10 issue 12, July 2017: 4.

Published 20 July 2017